Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: patients who are postmenopausal women or men who aged older than 50 years and meet the indications for osteoporosis treatment according to the Thai Osteoporosis Foundation's 2010 treatment guidelines.~* History of spinal or hip fractures with low energy trauma.~* BMD by Dual energy X-ray absorptiometry (DXA) scan with T-score ≤ -2.5 at the femoral neck, total hip, or L1-L4 spine.~* BMD by DXA scan with T-score between -1 and -2.5 at the femoral neck, total hip, or L1-L4 spine and a 10-year hip fracture probability ≥ 3% or a 10-year major osteoporosis-related fracture probability ≥ 20% based on Fracture risk assessment tool (FRAX)~Exclusion Criteria:~* Patients who have contraindications to use bisphosphonates e.g. gastroesophageal reflux disease or drug allergy to bisphosphonates~* Patients with an abnormality of serum calcium levels (more than 10.2 mg/dl or less than 8.7 mg/dl)~* Patients with estimated glomerular filtration rate less than 30 mL/min/1.73 m2~* Patients with metabolic bone diseases such as Paget's disease, hyperparathyroidism, etc.~* Patients who were received anti-osteoporotic drugs during the past 1 year.~* Patients who currently taking steroids, hormone replacement therapy, or selective estrogen receptor modulators (SERMs) within 1 year.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Original alendronate (Fosamax) (Type: NO_INTERVENTION): The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
- Generic alendronate (Bonmax) (Type: ACTIVE_COMPARATOR): The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).